Trial Profile
A phase I, open label study evaluating the pharmacokinetics of TX-001HR (1 mg E2/100 mg P4 or 0.5 mg E2/100 mg P4) in healthy post menopausal women
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 14 Apr 2020
Price :
$35
*
At a glance
- Drugs Estradiol/progesterone (Primary)
- Indications Endometrial hyperplasia; Menopausal syndrome
- Focus Pharmacokinetics
- 06 Oct 2018 Results assessing the Bioavailability of Estradiol and Progesterone for Moderate-to-Severe Vasomotor Symptom treatment with TX-001HR in REPLENISH and a Phase 1 trial, presented at the North American Menopause Society 2018 Annual Meeting
- 26 Apr 2018 New trial record
- 20 Mar 2018 Results presented at The 100th Annual Meeting of the Endocrine Society